We are proud to contribute to the scientific advancements on innate immunity and NK cells. Since our founding in 1999, our researchers have been published in several high impact factor journals, highlighting our expertise in NK cell modulation and commitment to the highest quality science.
Our approach is based on the development of therapeutic antibodies designed to stimulate the antitumor activity of immune system cells - not only to induce tumor elimination by innate immune system cells, but also to trigger a multicellular immune response leading to sustained tumor control.